Premium
Pathogen‐reduced platelets in pediatric and neonatal patients: Demographics, transfusion rates, and transfusion reactions
Author(s) -
Lasky Baia,
Nolasco Joseph,
Graff Jazmin,
Ward Dawn C.,
Ziman Alyssa,
McGonigle Andrea M.
Publication year - 2021
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.16639
Subject(s) - medicine , platelet transfusion , platelet , adverse effect , confidence interval , demographics , exact test , retrospective cohort study , medical record , pediatrics , surgery , demography , sociology
Background Pathogen‐reduced platelets (PR PLT) are the emerging standard for proactive transfusion‐transmitted infection (TTI) mitigation. There is, however, continued hesitation to transfuse PR PLT in children due to limited published data. We report demographics, rates of transfusion, and transfusion reactions (TR) associated with FDA‐approved PR PLT in pediatric and neonatal patients at an academic medical center. Methods Retrospective review was performed for patients <18 years receiving at least one platelet over a 300‐day period at a large, tertiary care hospital. Patients were transfused PR or conventional (CONV) PLT, based on inventory availability. Statistical analysis was performed using Fisher Exact Test. Results During the study period, 191 patients received 1010 platelet transfusions (892 units). Sixty‐eight patients received PR PLT only (1.3 units/patient, 95% confidence interval [CI] 1.1–1.5; 1.8 transfusions/patient, 95% CI 1.4–2.2), and 56 patients received CONV PLT only (1.4 units/patient, 95% CI 1.1–1.7; 1.6 transfusions/patient, 95% CI 1.3–1.9). Patients with hematologic malignancies undergoing chemotherapy/radiation and allogeneic hematopoietic stem cell transplant received the most platelet transfusions and more commonly received both platelet types. Of 506 PR PLT units, 5 TRs occurred; 386 CONV PLT resulted in two TRs ( p = .7052). Of 51 neonates, 37 received PR PLT without adverse events, including 13 receiving phototherapy. No TTIs were identified in any group. Conclusion There was no significant difference in rates of transfusion or TRs between PR and CONV PLT. Our study provides additional evidence that PR PLT can be transfused to pediatric and neonatal patients without increasing the risk of acute adverse events.